Please assess the completion status of the following clinical trial:

Trial Title: A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Nucleoside and nucleotide-naive subjects with chronic HBV infection~* Hepatitis B Surface antigen(HBsAg)-positive ≥6 months~* Detectable HBsAg~* HBV DNA ≥ 105 copies/mL by PCR~* ALT 1.3 to 10 x the ULN~* HBeAg negative, anti-hepatitis B Virus E antigen antibody (anti-HBeAb) positive status

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Entecavir + Lamivudine placebo (0-96 weeks)~Entecavir (96-240 weeks)
- Arm B (Type: ACTIVE_COMPARATOR): Lamivudine + Entecavir placebo (0-96 weeks)~Lamivudine (96-240 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).